Genmab A/S

GMAB · OMX

$43.79+$3.79 (+9.47%)TodayMarket closed · Oct 23, 7:57 PM ET

Prev close $40.00

Latest news

NewsOct 23, 11:57 AM ET
Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer
Press releaseOct 23, 11:56 AM ETBusiness Wire
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Press releaseOct 23, 11:55 AM ETGlobe Newswire
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Press releaseOct 14, 4:07 AM ETPRNewswire
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Press releaseOct 5, 2:54 PM ETPRNewswire
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Press releaseOct 5, 2:50 PM ETBusiness Wire
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Press releaseOct 5, 2:49 PM ETGlobe Newswire
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Press releaseOct 3, 3:40 PM ETBusiness Wire
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Press releaseJul 23, 4:00 PM ETBusiness Wire
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Press releaseJul 6, 1:45 PM ETBusiness Wire
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
NewsJun 30, 12:31 PM ETVandana Singh
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
NewsJun 30, 7:13 AM ET
Market-Moving News for June 30th
Press releaseJun 29, 4:15 PM ETBusiness Wire
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Press releaseJun 29, 4:14 PM ETGlobe Newswire
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Press releaseJun 13, 12:45 PM ETBusiness Wire
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Press releaseJun 11, 10:45 AM ETBusiness Wire
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
NewsJun 5, 1:30 PM ETKaustubh Bagalkote
Why Is ADC Therapeutics Stock Falling On Friday?
NewsJun 4, 8:44 AM ETVandana Singh
Why Is ADC Therapeutics Stock Falling Thursday?
Press releaseMay 21, 5:00 PM ETBusiness Wire
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Press releaseApr 13, 9:35 AM ETBusiness Wire
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
NewsFeb 19, 6:21 AM ETAvi Kapoor
Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1
NewsFeb 17, 4:24 PM ET
Genmab Q4 EPS $0.05 Misses $0.44 Estimate, Sales $1.058B Miss $4.401B Estimate
NewsFeb 17, 4:22 PM ET
Genmab: Q4 Earnings Insights
NewsFeb 17, 3:00 PM ET
A Glimpse Into The Expert Outlook On Genmab Through 4 Analysts
NewsFeb 16, 10:00 AM ET
A Peek at Genmab's Future Earnings
Press releaseJan 30, 10:36 AM ETPRNewswire
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
NewsJan 28, 9:00 AM ET
The Analyst Verdict: Genmab In The Eyes Of 4 Experts
NewsJan 20, 1:36 PM ETVandana Singh
Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside
Press releaseJan 16, 1:31 PM ETBusiness Wire
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NewsJan 16, 12:55 PM ET
Genmab A/S Shares Halted, News Pending
NewsJan 7, 12:06 PM ETAlex Perry
Why Are Investors Paying Attention To Genmab Stock?
Press releaseJan 7, 9:00 AM ETBusiness Wire
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
NewsJan 5, 11:59 AM ETVandana Singh
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
NewsDec 29, 12:32 PM ETVandana Singh
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
Press releaseDec 29, 8:12 AM ETBusiness Wire
Genmab Portfolio Prioritization Update
Press releaseDec 19, 7:44 AM ETPRNewswire
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Press releaseDec 12, 1:36 AM ETBusiness Wire
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Press releaseDec 8, 4:30 PM ETBusiness Wire
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Press releaseDec 7, 7:50 AM ETBusiness Wire
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
NewsNov 6, 4:29 PM ET
Genmab Q3 EPS $0.65, Sales $1.022B Beat $991.168M Estimate
Press releaseSep 29, 1:14 AM ETBusiness Wire
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Press releaseSep 29, 1:08 AM ETGlobe Newswire
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
NewsSep 24, 4:01 PM ET
Analyst Expectations For Genmab's Future
Press releaseAug 12, 2:36 PM ETGlobe Newswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Press releaseJun 17, 1:34 PM ETGlobe Newswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

Market-Moving News for June 30th

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Why Is ADC Therapeutics Stock Falling On Friday?

Why Is ADC Therapeutics Stock Falling Thursday?

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1

Genmab Q4 EPS $0.05 Misses $0.44 Estimate, Sales $1.058B Miss $4.401B Estimate

Genmab: Q4 Earnings Insights

A Glimpse Into The Expert Outlook On Genmab Through 4 Analysts

A Peek at Genmab's Future Earnings

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

The Analyst Verdict: Genmab In The Eyes Of 4 Experts

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab A/S Shares Halted, News Pending

Why Are Investors Paying Attention To Genmab Stock?

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer

Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets

Genmab Portfolio Prioritization Update

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Genmab Q3 EPS $0.65, Sales $1.022B Beat $991.168M Estimate

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Analyst Expectations For Genmab's Future

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise